Acupuncture points for fatty liver are specific locations on the body used in Traditional Chinese Medicine (TCM) to address liver-related conditions, though their use is not supported by NHS or NICE guidance. Fatty liver disease, affecting approximately one in three UK adults, occurs when excess fat accumulates in liver cells. Whilst some patients explore acupuncture alongside conventional management, the evidence base remains limited. NICE guideline NG49 emphasises lifestyle modification—including weight loss of 7–10%, dietary changes, and physical activity—as the cornerstone of treatment. Acupuncture should only be considered as a complement to, never a replacement for, evidence-based medical care and regular monitoring.

Understanding Fatty Liver Disease and Treatment Options

Fatty liver disease, medically termed hepatic steatosis, occurs when excess fat accumulates in liver cells, comprising more than 5% of the liver's weight. This condition exists in two primary forms: non-alcoholic fatty liver disease (NAFLD), which affects individuals who consume little to no alcohol, and alcoholic fatty liver disease (AFLD), directly related to excessive alcohol intake. NAFLD has become increasingly prevalent in the UK, affecting approximately one in three adults, often associated with obesity, type 2 diabetes, and metabolic syndrome.

The liver performs over 500 vital functions, including detoxification, protein synthesis, and metabolic regulation. When fat accumulates, it can progress from simple steatosis to non-alcoholic steatohepatitis (NASH), characterised by inflammation and potential liver cell damage. Without intervention, this may advance to fibrosis, cirrhosis, or hepatocellular carcinoma. Early-stage fatty liver disease typically presents without symptoms, though some patients report fatigue, discomfort in the upper right abdomen, or general malaise.

Initial assessment typically involves a clinical history (including alcohol consumption and metabolic risk factors), liver function tests, and imaging such as ultrasound where appropriate. In primary care, non-invasive fibrosis risk scores such as the FIB-4 or NAFLD Fibrosis Score may be used to identify patients who require further assessment with tests such as the Enhanced Liver Fibrosis (ELF) blood test or transient elastography (FibroScan), in line with local pathways and NICE guidance.

Conventional treatment approaches focus primarily on lifestyle modification, as no licensed pharmacological therapy currently exists specifically for NAFLD in the UK. The cornerstone of management includes:

• Weight reduction of 7–10% through caloric restriction and increased physical activity

• Dietary modifications emphasising Mediterranean-style eating patterns aligned with the NHS Eatwell Guide

• Physical activity of at least 150 minutes of moderate-intensity aerobic exercise weekly

• Management of comorbidities such as diabetes (with metformin as first-line therapy for glycaemic control per NICE NG28), hypertension, and dyslipidaemia

• Statins are safe in NAFLD and should be prescribed when indicated for cardiovascular risk or dyslipidaemia; they should not be withheld because of fatty liver disease

• Alcohol guidance differs by condition: for NAFLD, keep within UK Chief Medical Officers' low-risk drinking guidelines (no more than 14 units weekly, spread over three or more days, with alcohol-free days); for alcoholic liver disease, abstinence is the standard recommendation

• Regular monitoring through blood tests and imaging

• Referral to specialist hepatology services for advanced fibrosis (stage F3 or F4), diagnostic uncertainty, or failure to respond to lifestyle interventions

Patients with cirrhosis or advanced fibrosis may require hepatocellular carcinoma (HCC) surveillance with six-monthly ultrasound (± alpha-fetoprotein) as per specialist guidance.

Some patients explore complementary approaches, including acupuncture, alongside conventional management. However, it remains essential that any complementary therapy is used as an adjunct to, rather than replacement for, evidence-based lifestyle interventions and medical supervision. The NHS and NICE do not currently recommend acupuncture for NAFLD.

Further information:

• NICE guideline NG49: Non-alcoholic fatty liver disease – assessment and management

• NHS: Non-alcoholic fatty liver disease (NAFLD)

• British Liver Trust: NAFLD information

• UK Chief Medical Officers' low-risk drinking guidelines (GOV.UK)

Acupuncture Points Used for Fatty Liver in Traditional Medicine

Traditional Chinese Medicine (TCM) conceptualises fatty liver disease differently from Western biomedicine, viewing it as a manifestation of imbalances involving liver qi stagnation, spleen deficiency, dampness accumulation, and phlegm retention. TCM practitioners believe these patterns disrupt the body's ability to metabolise and transport nutrients effectively, leading to pathological fat accumulation in the liver. It is important to note that TCM concepts are not part of NHS or biomedical frameworks, and the evidence base for acupuncture in treating fatty liver disease is limited.

In acupuncture practice for liver-related conditions, practitioners typically select from several key acupoint categories:

Liver meridian points are considered primary targets:

• Liver 3 (Taichong) – located on the foot between the first and second metatarsal bones, traditionally used to regulate liver qi and reduce stagnation

• Liver 13 (Zhangmen) – positioned on the lateral abdomen, regarded as the influential point for the solid organs

• Liver 14 (Qimen) – found below the nipple line on the chest, considered the liver's alarm point

Spleen and stomach meridian points address digestive and metabolic functions:

• Stomach 36 (Zusanli) – below the knee on the anterior leg, widely used for strengthening digestive function

• Spleen 6 (Sanyinjiao) – on the inner lower leg, believed to tonify spleen function and resolve dampness

• Spleen 9 (Yinlingquan) – at the inner knee, traditionally selected for draining dampness

Additional points may include:

• Ren 12 (Zhongwan) – on the upper abdomen, considered influential for digestive organs

• Gallbladder 34 (Yanglingquan) – lateral to the knee, regarded as influential for tendons and often combined with liver points

TCM practitioners typically individualise point selection based on diagnostic patterns identified through pulse diagnosis, tongue examination, and symptom presentation.

Important safety information:

• Do not attempt self-needling or acupuncture at home. Acupuncture should only be performed by suitably qualified and registered practitioners.

• Practitioners must use sterile single-use needles and adhere to strict infection control standards in licensed premises.

• Certain points, such as Spleen 6, are generally avoided during pregnancy due to traditional contraindications.

• Chest points such as Liver 14 carry a risk of pneumothorax (collapsed lung) if performed incorrectly and require advanced training and careful technique.

• Electroacupuncture should generally be avoided in people with pacemakers or implantable cardioverter-defibrillators (ICDs).

• Always inform your acupuncturist of any medical conditions, medications (especially anticoagulants), pregnancy, or implanted devices.

Further information:

• NHS: Acupuncture – safety and risks

• British Acupuncture Council (BAcC) – Code of Safe Practice

• Professional Standards Authority (PSA) Accredited Registers

Clinical Evidence for Acupuncture in Liver Health

The scientific evidence base for acupuncture in fatty liver disease remains limited and of variable quality. Whilst some studies, predominantly from China, have reported potential benefits, methodological limitations prevent definitive conclusions about efficacy.

Systematic reviews examining acupuncture for NAFLD have identified several randomised controlled trials suggesting improvements in liver enzyme levels (ALT, AST) and hepatic steatosis on imaging when acupuncture was combined with lifestyle modification compared to lifestyle changes alone. However, these studies frequently exhibited significant methodological weaknesses, including small sample sizes, inadequate blinding (particularly difficult with acupuncture versus sham controls), short follow-up periods, heterogeneous outcome measures, and potential publication bias. The quality of evidence was generally rated as low to very low according to GRADE (Grading of Recommendations Assessment, Development and Evaluation) criteria.

Proposed mechanisms by which acupuncture might theoretically influence metabolic health remain speculative and include:

• Modulation of autonomic nervous system activity, potentially affecting metabolic rate

• Influence on inflammatory cytokine production

• Effects on insulin sensitivity through neuroendocrine pathways

• Alterations in appetite-regulating hormones such as ghrelin and leptin

These mechanisms require further research and should be regarded as theoretical rather than established.

Animal studies have demonstrated that electroacupuncture may reduce hepatic lipid accumulation and improve insulin resistance in rodent models of fatty liver disease. These effects appear mediated through activation of AMP-activated protein kinase (AMPK) pathways and reduction in hepatic lipogenesis. However, translating animal research to human clinical benefit remains speculative, and findings in rodent models do not necessarily predict outcomes in people.

Critically, there is no robust evidence that acupuncture alone can reverse established fatty liver disease or prevent progression to advanced liver disease. No UK body, including NICE or the NHS, recommends acupuncture for NAFLD. The European Association for the Study of the Liver (EASL) clinical practice guidelines do not include acupuncture as a recommended intervention. Any potential benefits likely depend on concurrent lifestyle modification, and acupuncture should not be considered a substitute for weight loss, dietary improvement, and management of metabolic risk factors.

Further information:

• NICE guideline NG49: Non-alcoholic fatty liver disease – assessment and management

• EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease

NHS and NICE Guidance on Fatty Liver Management

NICE guidance provides clear, evidence-based recommendations for managing non-alcoholic fatty liver disease in the UK. The primary guideline (NG49: Non-alcoholic fatty liver disease – assessment and management, 2016) emphasises lifestyle intervention as the cornerstone of treatment. Acupuncture and other complementary therapies are not mentioned as recommended interventions.

Key NICE recommendations include:

For diagnosis and assessment:

• Use of the Enhanced Liver Fibrosis (ELF) blood test to assess advanced fibrosis in adults with NAFLD, as specifically recommended by NICE NG49

• In primary care, FIB-4 or NAFLD Fibrosis Score may be used as initial risk stratification tools, with onward testing (ELF or transient elastography) according to local pathways

• Liver biopsy reserved for cases where diagnosis remains uncertain, advanced disease is suspected, or other liver pathology needs exclusion

• Regular monitoring of liver function tests, lipid profiles, and glycaemic control

For lifestyle management:

• Weight loss target of 7–10% of body weight for adults with NAFLD, achieved through reduced caloric intake and increased physical activity

• Dietary advice aligned with the NHS Eatwell Guide, emphasising whole grains, fruits, vegetables, and limiting saturated fats and refined sugars

• Physical activity of at least 150 minutes of moderate-intensity aerobic exercise weekly

• Alcohol consumption: for NAFLD, keep within UK Chief Medical Officers' low-risk drinking guidelines (no more than 14 units weekly, spread over three or more days, with alcohol-free days); for alcoholic liver disease, abstinence is the standard recommendation

• Signposting to NHS weight management services and local support programmes where available

For comorbidity management:

• Diabetes control: metformin is first-line therapy for type 2 diabetes (NICE NG28) to achieve glycaemic control; it is not recommended specifically to treat NAFLD itself

• Lipid management: statins are safe in NAFLD and should be prescribed when indicated for cardiovascular risk or dyslipidaemia; do not withhold statins because of fatty liver disease

• Treatment of hypertension according to cardiovascular risk

• Consideration of bariatric surgery for eligible patients with severe obesity

Specialist therapies: NICE NG49 advises that pioglitazone or vitamin E may be considered off-label in carefully selected adults with biopsy-proven NASH and advanced fibrosis, but only in specialist settings after discussion of risks and benefits.

NHS services typically manage fatty liver disease through primary care, with referral to hepatology services for:

• Advanced fibrosis (stage F3 or F4) identified on non-invasive testing (ELF, transient elastography)

• Indeterminate or abnormal results on fibrosis assessment requiring specialist interpretation

• Diagnostic uncertainty or coexistent liver conditions

• Failure to respond to lifestyle interventions

The absence of complementary therapies from NICE guidance reflects the current evidence base. Patients considering acupuncture should discuss this with their GP to ensure it does not delay or replace evidence-based interventions. Any complementary approach must be integrated within a comprehensive management plan centred on lifestyle modification and medical monitoring.

Further information:

• NICE guideline NG49: Non-alcoholic fatty liver disease – assessment and management

• NICE guideline NG28: Type 2 diabetes in adults – management

• NHS: Non-alcoholic fatty liver disease (NAFLD)

• UK Chief Medical Officers' low-risk drinking guidelines (GOV.UK)

• NHS Eatwell Guide

Safety Considerations and When to Seek Medical Advice

Whilst acupuncture is generally considered safe when performed by qualified practitioners using appropriate standards, several important safety considerations apply, particularly for individuals with liver disease.

Acupuncture safety profile: When delivered by registered practitioners adhering to appropriate hygiene and infection control standards, acupuncture carries a low risk of serious adverse events. Common minor effects include:

• Temporary pain, bruising, or bleeding at needle insertion sites

• Transient fatigue or light-headedness

• Minor autonomic responses such as sweating or nausea

Specific concerns for liver disease patients:

• Individuals with advanced liver disease may have impaired coagulation due to reduced synthesis of clotting factors, increasing bleeding risk

• Those with cirrhosis and portal hypertension may have thrombocytopenia (low platelet counts), further elevating bleeding risk

• Patients must inform acupuncturists about any anticoagulant or antiplatelet medications (warfarin, direct oral anticoagulants, aspirin, clopidogrel)

Essential safety standards:

• Practitioners must use sterile single-use needles and follow strict infection prevention and control procedures

• Treatment should take place in licensed premises that meet local authority and professional body standards

• Pregnancy: certain acupuncture points (e.g., Spleen 6) are traditionally avoided during pregnancy; always inform your practitioner if you are or might be pregnant

• Pacemakers and ICDs: electroacupuncture should generally be avoided in people with pacemakers or implantable cardioverter-defibrillators

• Pneumothorax risk: chest points (e.g., Liver 14) carry a risk of pneumothorax if performed incorrectly and require advanced training and careful technique

Practitioner qualifications: In the UK, acupuncture is not statutorily regulated, though professional bodies maintain registers. Patients should seek practitioners registered with:

• British Acupuncture Council (BAcC)

• Professional Standards Authority (PSA) Accredited Registers

• Healthcare professionals with additional acupuncture training (physiotherapists, doctors, nurses)

When to seek urgent medical advice: Patients with fatty liver disease should contact their GP or seek emergency care if they experience:

• Jaundice (yellowing of skin or eyes)

• Abdominal swelling or pain that is severe or worsening

• Confusion or altered mental state (potential hepatic encephalopathy)

• Vomiting blood or passing black, tarry stools

• Unexplained bruising or bleeding

• Persistent fever with abdominal symptoms

• Severe chest pain or breathlessness following acupuncture (possible pneumothorax)

Reporting adverse effects: If you experience a suspected side effect or adverse incident related to acupuncture or any other treatment, you can report it via the MHRA Yellow Card Scheme at https://yellowcard.mhra.gov.uk or through the Yellow Card app.

Important principles:

• Never use acupuncture as a substitute for medical investigation of abnormal liver function tests

• Continue all prescribed medications (including statins) unless advised otherwise by your doctor

• Maintain regular monitoring appointments with your GP or hepatologist

• Prioritise evidence-based lifestyle changes as the primary intervention for fatty liver disease

• Inform all healthcare providers (GP, hepatologist, acupuncturist) about all treatments and therapies you are using

Patients considering acupuncture should have an open discussion with their GP to ensure it complements rather than compromises their overall management plan. The most important determinant of outcomes in fatty liver disease remains sustained lifestyle modification, and no complementary therapy should distract from this fundamental approach.

Further information:

• NHS: Acupuncture – safety and risks

• British Acupuncture Council (BAcC) – Code of Safe Practice

• MHRA Yellow Card Scheme (for reporting adverse effects)

• NICE guideline NG49: Non-alcoholic fatty liver disease – assessment and management

Frequently Asked Questions